Investigational drug · Phase 3
TAF
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HIV-1-infection, Chronic Hepatitis B.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
357
Any phase or sponsor naming "TAF"
First trial start
2016
Nov 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TAF", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV-1-infection
- Chronic Hepatitis B
Approved drugs for the same conditions: HIV · Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "TAF" as an intervention, largest first.
Huashan HospitalAcademic, hospital or other
NCT05937178 · 20,000 participants (planned) · Start Jan 31, 2023 · Primary completion Jan 31, 2029
Drug: ETV/TAF/TDF/TMF/IFN; ETV/TAF/TDF/TMF · For: Hepatitis B, Chronic
Sites: Hefei, China; Beijing, China; Chongqing, China · 44 sites in all
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT07169656 · 15,000 participants (planned) · Start Jun 3, 2024 · Primary completion Jun 30, 2032
Drug: ETV,TDF,TAF,TMF; Peginterferon α-2b injection · For: Chronic Hepatitis b
Sites: Anyang, China; Guangzhou, China; Hebi, China · 162 sites in all
- Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB PatientsStatus unknown
The Second Affiliated Hospital of Chongqing Medical UniversityAcademic, hospital or other
NCT04724785 · 10,000 participants (planned) · Start Dec 1, 2020 · Primary completion Jul 1, 2022
Drug: regimen change · For: Sustained Virologic Response; Hepatitis B, Chronic
Sites: Chongqing, China
- Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort ApproachNot yet recruiting
The Task Force for Global HealthAcademic, hospital or other
NCT07258251 · 6,000 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2028
Drug: Tenofovir Alafenamide (TAF) · For: Chronic Hepatitis B; Hepatitis B Virus Infection
Sites: Phichit, Thailand
Gilead SciencesGilead Sciences (GILD)
NCT02842086 · 5,399 participants · Start Sep 2, 2016 · Primary completion Jan 31, 2019
Drug: F/TAF; F/TDF and 2 more · For: Pre-Exposure Prophylaxis of HIV-1 Infection
Sites: Beverly Hills, California; Los Angeles, California; Newport Beach, California · 93 sites in all
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04994509 · 5,368 participants · Start Aug 30, 2021 · Primary completion May 27, 2024
Drug: Oral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN) and 6 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Brits, South Africa; Cape Town, South Africa; Durban, South Africa · 28 sites in all
- Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral TherapyNot yet recruiting
Wen-hong ZhangAcademic, hospital or other
NCT05965388 · 5,000 participants (planned) · Start Dec 1, 2023 · Primary completion Feb 1, 2029
Drug: nucleoside analogues or interferon · For: HBV; HCC
Sites: Hefei, China; Fuzhou, China; Wuhan, China · 10 sites in all
Third Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT05182463 · 5,000 participants (planned) · Start Jan 8, 2022 · Primary completion Dec 13, 2026
Drug: Peginterferon Alfa-2B; Nucleoside Analogs · For: Hepatitis B, Chronic
Sites: Guangzhou, China
- Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04925752 · 3,292 participants · Start Jun 28, 2021 · Primary completion Aug 21, 2024
Drug: Oral Lenacapavir (LEN); F/TDF and 5 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 93 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT07473778 · 3,000 participants (planned) · Start Mar 17, 2026 · Primary completion Apr 2028
Drug: Lenacapavir Injection; Emtricitabine/tenofovir disoproxil fumarate (F/TDF) and 3 more · For: HIV Infections
Sites: Birmingham, Alabama; Beverly Hills, California; Los Angeles, California · 44 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Genetically engineered extracellular vesicles with chimeric antigen receptors of human stem cell-derived neutrophils targeting fibroblast activation protein to modulate tumor microenvironment.
Esmonde C, Sun L, Jin G, et al. · Bioact Mater 2027
- Evaluation of dried blood spots relative to peripheral blood mononuclear cells for intracellular tenofovir-diphosphate and emtricitabine-triphosphate assessment using liquid chromatography-tandem mass spectrometry.
Lin YT, Sun HY, Cheng CN, et al. · J Pharm Biomed Anal 2027
- Efficacy and metabolic outcomes of switching from an INSTI-based triple-drug regimen to dolutegravir/lamivudine in treatment-experienced HIV-1-infected patients: a 48-week real-world study.
Zhang W, Li Q, Deng C, et al. · Ann Med 2026
- A temporary fix: assessing the safety, efficacy, and various applications of temporary externalized pacemakers.
Schiefer L, Sheppard G, King A, et al. · Proc (Bayl Univ Med Cent) 2026
- Virological and immunological outcomes of BIC/TAF/FTC versus DTGߙ+ߙTDF/FTC in treatment-naïve people with HIV: a real-world study.
Ozdemir YE, Camber L, Ertay BNO, et al. · Ir J Med Sci 2026
- Long-Term Five-Year Effectiveness of Tenofovir Alafenamide in Japanese Patients With Chronic Hepatitis B: A Prospective Multicenter Registry Study.
Takada H, Tamaki N, Ochi H, et al. · JGH Open 2026
Also in development for HIV-1-infection
- GS-3242Phase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- LEN FDCPhase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- OBRPhase 32 trials
Gilead Sciences · HIV-1-infection
- TMB-365TMB-380, VRC07523LSPhase 23 trials
TaiMed Biologics Inc. · HIV-1-infection, HIV -1 Infection
- CAP256V2LSPhase 21 trial
Gilead Sciences · HIV-1-infection
- PirmitegravirPhase 21 trial
ST Pharm Co., Ltd. · HIV-1-infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.